Alphabet life sciences再增7亿美元，为新冠研究加持！

Alphabet旗下的生命科学（life sciences）部门Verily，已经筹集了7亿美元的新资金，用于扩大其商业业务，包括其临床医疗平台Baseline，该平台已经用于新冠研究。

这笔投资不仅来自Alphabet，还来自谷歌母公司以外的其他投资者。Verily还表示，它还将利用这些资金来推进其几个生命科学项目，包括外科、病理学和免疫学。

去年3月，该公司为新冠患者推出了Project Baseline的网站。之后在5月，该公司表示将启动针对该病毒的抗体研究。 夏天，在南旧金山开设了一个临床实验室，为新冠测试创造更多的实验室能力。

Verily, Alphabet's life sciences unit, has raised $700 million in new funding to expand its business operations, including its clinical medical platform Baseline, which has been used for COVID-19 research.

This investment not only comes from Alphabet, but also from other investors outside of Google's parent company. Verily also stated that it will also use the funds to advance several of its life science projects, including surgery, pathology and immunology.

In March last year, the company launched the Project Baseline website for COVID-19 patients. Later in May, the company said it would start antibody research against the virus. In the summer, a clinical laboratory was opened in South San Francisco to create more laboratory capacity for COVID-19 testing.  source

指尖新闻：高信噪比，一目了然

新冠疫情追踪